Abstract
Systemic inflammatory diseases could produce neurologic complications, and they are frequently incorporated in the differential diagnosis of neurological symptoms. There are wellestablished criteria to meet the diagnosis of neurologic manifestations of these systemic diseases.
Methods: However, the range of clinical presentations varies in each condition, and the prevalence of these complications differs between studies. Hence, in many cases, an etiological relationship is not clearly defined.
Results and Conclusion: For these reasons, it is challenging to make an accurate diagnosis. We analyzed the spectrum of neurological manifestations in a cohort of patients with systemic lupus erythematosus, rheumatoid arthritis, Behçet disease and sarcoidosis in order to improve our current knowledge of these complications.
Keywords: Systemic lupus erythematosus, rheumatoid arthritis, Behçet disease, sarcoidosis, systemic inflammatory diseases, neurological manifestations.
[1]
Bhattacharyya S, Helfgott SM. Neurologic complications of systemic lupus erythematosus, Sjögren syndrome, and rheumatoid arthritis. Semin Neurol 2014; 34(4): 425-36.
[http://dx.doi.org/10.1055/s-0034-1390391] [PMID: 25369438]
[http://dx.doi.org/10.1055/s-0034-1390391] [PMID: 25369438]
[2]
Atzeni F, Talotta R, Masala IF, Gerardi MC, Casale R, Sarzi-Puttini P. Central nervous system involvement in rheumatoid arthritis patients and the potential implications of using biological agents. Best Pract Res Clin Rheumatol 2018; 32(4): 500-10.
[http://dx.doi.org/10.1016/j.berh.2019.02.003] [PMID: 31174819]
[http://dx.doi.org/10.1016/j.berh.2019.02.003] [PMID: 31174819]
[3]
The American College of rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42(4): 599-608.
[http://dx.doi.org/10.1002/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F] [PMID: 10211873]
[http://dx.doi.org/10.1002/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F] [PMID: 10211873]
[4]
DeQuattro K, Imboden JB. Neurologic manifestations of rheumatoid arthritis. Rheum Dis Clin North Am 2017; 43(4): 561-71.
[http://dx.doi.org/10.1016/j.rdc.2017.06.005] [PMID: 29061242]
[http://dx.doi.org/10.1016/j.rdc.2017.06.005] [PMID: 29061242]
[5]
Joaquim AF, Appenzeller S. Neuropsychiatric manifestations in rheumatoid arthritis. Autoimmun Rev 2015; 14(12): 1116-22.
[http://dx.doi.org/10.1016/j.autrev.2015.07.015] [PMID: 26238502]
[http://dx.doi.org/10.1016/j.autrev.2015.07.015] [PMID: 26238502]
[6]
International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet 1990; 335(8697): 1078-80.
[PMID: 1970380]
[PMID: 1970380]
[7]
Peño IC, De las Heras Revilla V, Carbonell BP, et al. Neurobehçet disease: Clinical and demographic characteristics. Eur J Neurol 2012; 19(9): 1224-7.
[http://dx.doi.org/10.1111/j.1468-1331.2012.03706.x] [PMID: 22469257]
[http://dx.doi.org/10.1111/j.1468-1331.2012.03706.x] [PMID: 22469257]
[8]
Akman-Demir G, Serdaroglu P, Tasçi B. The Neuro-Behçet Study Group. Clinical patterns of neurological involvement in Behçet’s disease: Evaluation of 200 patients. Brain 1999; 122(Pt 11): 2171-82.
[http://dx.doi.org/10.1093/brain/122.11.2171] [PMID: 10545401]
[http://dx.doi.org/10.1093/brain/122.11.2171] [PMID: 10545401]
[9]
Kalra S, Silman A, Akman-Demir G, et al. Diagnosis and management of Neuro-Behçet’s disease: International consensus recommendations. J Neurol 2014; 261(9): 1662-76.
[http://dx.doi.org/10.1007/s00415-013-7209-3] [PMID: 24366648]
[http://dx.doi.org/10.1007/s00415-013-7209-3] [PMID: 24366648]
[10]
Borhani-Haghighi A, Kardeh B, Banerjee S, et al. Neuro-Behcet’s disease: An update on diagnosis, differential diagnoses, and treatment. Mult Scler Relat Disord 2019; 39: 101906.
[http://dx.doi.org/10.1016/j.msard.2019.101906] [PMID: 31887565]
[http://dx.doi.org/10.1016/j.msard.2019.101906] [PMID: 31887565]
[11]
Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis 2018; 77(6): 808-18.
[http://dx.doi.org/10.1136/annrheumdis-2018-213225] [PMID: 29625968]
[http://dx.doi.org/10.1136/annrheumdis-2018-213225] [PMID: 29625968]
[12]
Riera-Mestre A, Martínez-Yélamos S, Martínez-Yélamos A, Vidaller A, Pujol R. Neuro-Behçet and neurotoxicity due to cyclosporine. Rev Clin Esp 2008; 208(4): 205-6.
[http://dx.doi.org/10.1157/13117047] [PMID: 18381009]
[http://dx.doi.org/10.1157/13117047] [PMID: 18381009]
[13]
Martin M, Gil H, Hafsaoui C, Meaux-Ruault N, Magy-Bertrand N. Role of cyclosporine in the occurrence of neuro-Behçet’s disease? Rev Med Interne 2010; 31(11): e7-8.
[http://dx.doi.org/10.1016/j.revmed.2010.02.010] [PMID: 20554093]
[http://dx.doi.org/10.1016/j.revmed.2010.02.010] [PMID: 20554093]
[15]
Bargagli E, Prasse A. Sarcoidosis: A review for the internist. Intern Emerg Med 2018; 13(3): 325-31.
[PMID: 29299831]
[PMID: 29299831]
[16]
Luisetti M, Beretta A, Casali L. Genetic aspects in sarcoidosis. Eur Respir J 2000; 16(4): 768-80.
[http://dx.doi.org/10.1034/j.1399-3003.2000.16d31.x] [PMID: 11106224]
[http://dx.doi.org/10.1034/j.1399-3003.2000.16d31.x] [PMID: 11106224]
[17]
Moller DR, Chen ES. Genetic basis of remitting sarcoidosis: Triumph of the trimolecular complex? Am J Respir Cell Mol Biol 2002; 27(4): 391-5.
[http://dx.doi.org/10.1165/rcmb.2002-0164PS] [PMID: 12356571]
[http://dx.doi.org/10.1165/rcmb.2002-0164PS] [PMID: 12356571]
[18]
Stern BJ, Royal W III, Gelfand JM, et al. Definition and consensus diagnostic criteria for neurosarcoidosis: From the neurosarcoidosis consortium consensus group. JAMA Neurol 2018; 75(12): 1546-53.
[http://dx.doi.org/10.1001/jamaneurol.2018.2295] [PMID: 30167654]
[http://dx.doi.org/10.1001/jamaneurol.2018.2295] [PMID: 30167654]
[19]
Fritz D, van de Beek D, Brouwer MC. Clinical features, treatment and outcome in neurosarcoidosis: Systematic review and meta-analysis. BMC Neurol 2016; 16(1): 220.
[http://dx.doi.org/10.1186/s12883-016-0741-x] [PMID: 27846819]
[http://dx.doi.org/10.1186/s12883-016-0741-x] [PMID: 27846819]
[20]
World Medical Association. World medical association declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 2013; 310(20): 2191-4.
[http://dx.doi.org/10.1001/jama.2013.281053] [PMID: 24141714]
[http://dx.doi.org/10.1001/jama.2013.281053] [PMID: 24141714]
[21]
Seoane-Mato D, Sánchez-Piedra C, Silva-Fernández L, et al. Prevalence of rheumatic diseases in adult population in Spain (EPISER 2016 study): Aims and methodology. Reumatol Clin 2019; 15(2): 90-6.
[http://dx.doi.org/10.1016/j.reumae.2018.10.004] [PMID: 28774657]
[http://dx.doi.org/10.1016/j.reumae.2018.10.004] [PMID: 28774657]
[22]
Rúa-Figueroa I, López-Longo FJ, Calvo-Alén J, et al. National registry of patients with systemic lupus erythematosus of the Spanish Society of Rheumatology: Objectives and methodology. Reumatol Clin 2014; 10(1): 17-24.
[http://dx.doi.org/10.1016/j.reumae.2013.11.006] [PMID: 23871155]
[http://dx.doi.org/10.1016/j.reumae.2013.11.006] [PMID: 23871155]
[23]
Pons-Estel GJ, Andreoli L, Scanzi F, Cervera R, Tincani A. The antiphospholipid syndrome in patients with systemic lupus erythematosus. J Autoimmun 2017; 76: 10-20.
[http://dx.doi.org/10.1016/j.jaut.2016.10.004] [PMID: 27776934]
[http://dx.doi.org/10.1016/j.jaut.2016.10.004] [PMID: 27776934]
[24]
Bortoluzzi A, Silvagni E, Furini F, Piga M, Govoni M. Peripheral nervous system involvement in systemic lupus erythematosus: A review of the evidence. Clin Exp Rheumatol 2019; 37(1): 146-55.
[PMID: 29846158]
[PMID: 29846158]
[26]
García-Palenzuela R, Graña Gil J, Varela Arias M, Tovar Bobo M. Update of Behçet disease. A presentation of 2 cases in primary care. Semergen 2012; 38(1): 33-9.
[PMID: 24847537]
[PMID: 24847537]
[27]
Fabrellas FE. Epidemiology of sarcoidosis. Arch Bronconeumol 2007; 43(2): 92-100.
[http://dx.doi.org/10.1157/13098420] [PMID: 17288898]
[http://dx.doi.org/10.1157/13098420] [PMID: 17288898]
Article Metrics
33
3
